Bayer Yakuhin Ltd. Has Filed Fosrenol(R) For The Treatment Of Hyperphosphatemia In Japan

Published: Dec 20, 2006

Osaka, Japan, Dec 20, 2006 - (JCN Newswire) - Bayer Yakuhin Ltd. has submitted a marketing application for Fosrenol(R) (lanthanum carbonate) for the treatment of hyperphosphatemia in end stage renal disease (ESRD) patients in Japan. Bayer Yakuhin received an exclusive license from Shire International Licensing BV in December, 2003 to develop and sell Fosrenol(R) in Japan and completed Phase II and Phase III clinical trials in Japan.

Back to news